As Bio Rad Labs INC (BIO) Stock Price Rose, Polar Securities INC Has Cut Its Position by $3.15 Million

September 3, 2018 - By Theresa McIntyre

Bio-Rad Laboratories, Inc. (NYSE:BIO) LogoInvestors sentiment decreased to 1.03 in 2018 Q1. Its down 0.10, from 1.13 in 2017Q4. It worsened, as 18 investors sold BIO shares while 101 reduced holdings. 42 funds opened positions while 81 raised stakes. 18.53 million shares or 0.19% less from 18.57 million shares in 2017Q4 were reported. Proshare Ltd Co stated it has 2,230 shares or 0% of all its holdings. Victory Mngmt has 7,306 shares. Pnc Finance Group, Pennsylvania-based fund reported 7,752 shares. Tiaa Cref Mgmt Ltd Liability Company reported 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO). Art Advisors Limited Liability Company has invested 0.04% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Oregon Employees Retirement Fund holds 0.03% or 7,605 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt Systems invested in 0.02% or 5,450 shares. The Minnesota-based Ameriprise Inc has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Adage Prns Gru Limited Liability Company, a Massachusetts-based fund reported 75,000 shares. Hbk Invs LP invested in 0.01% or 3,000 shares. Liberty Mutual Group Inc Asset has 3,981 shares. Intrepid Cap Mngmt holds 0.31% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 3,664 shares. Hermes Investment Management holds 0.7% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 192,311 shares. Thrivent Financial For Lutherans holds 0% or 4,580 shares in its portfolio. Virginia Retirement Sys Et Al accumulated 0.01% or 3,600 shares.

Since June 13, 2018, it had 0 insider buys, and 1 sale for $106,197 activity.

Polar Securities Inc decreased its stake in Bio Rad Labs Inc (BIO) by 7.65% based on its latest 2018Q1 regulatory filing with the SEC. Polar Securities Inc sold 12,612 shares as the company’s stock rose 11.67% while stock markets declined. The institutional investor held 152,178 shares of the capital goods company at the end of 2018Q1, valued at $38.06 million, down from 164,790 at the end of the previous reported quarter. Polar Securities Inc who had been investing in Bio Rad Labs Inc for a number of months, seems to be less bullish one the $9.67B market cap company. The stock decreased 0.15% or $0.48 during the last trading session, reaching $325.3. About 66,896 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 30.04% since September 3, 2017 and is uptrending. It has outperformed by 17.47% the S&P500.

Polar Securities Inc, which manages about $6.06 billion US Long portfolio, upped its stake in Transalta Corp (NYSE:TAC) by 4.10 million shares to 4.21 million shares, valued at $22.95 million in 2018Q1, according to the filing. It also increased its holding in Agilent Technologies Inc (NYSE:A) by 103,300 shares in the quarter, for a total of 386,400 shares, and has risen its stake in Ishares Tr (Put) (IWM).

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on November, 1. They expect $1.02 earnings per share, up 12.09 % or $0.11 from last year’s $0.91 per share. BIO’s profit will be $30.31M for 79.73 P/E if the $1.02 EPS becomes a reality. After $1.64 actual earnings per share reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts -37.80 % negative EPS growth.

More news for Bio-Rad Laboratories, Inc. (NYSE:BIO) were recently published by: Benzinga.com, which released: “The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex’s Precision Medicine Collaboration” on August 30, 2018. Seekingalpha.com‘s article titled: “Bio-Rad Laboratories (BIO) Q2 2018 Results – Earnings Call Transcript” and published on August 07, 2018 is yet another important article.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 2 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories had 2 analyst reports since March 20, 2018 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Wednesday, August 8. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) earned “Buy” rating by Wells Fargo on Tuesday, March 20.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.